09.12.2013 • News

Evonik and LanzaTech in Bioprocessed Plastics Precursors R&D

Germany's Evonik and U.S.-headquartered LanzaTech have signed a three year research cooperation pact linking the German company's existing biotechnology platforms with the U.S. partner's synthetic biology and gas fermentation expertise to produce bioprocessed precursors for specialty plastics.

At the heart of the agreement is a technology that uses microorganisms placed in fermenters to convert synthesis gas into chemical products. The gases will be derived either from carbon monoxide or carbon dioxide and hydrogen and may come from a variety of gasified biomass waste streams including forestry and agricultural residues and gasified municipal solid waste.

"Industrial biotechnology is one of the core competences of Evonik. It enables new approaches to specialty chemicals and processes," said Stefan Buchholz, head of the company's strategic innovation arm, Creavis. "The use of renewables and specific waste streams is one of the main focuses of our research and development work, and LanzaTech offers an additional interesting approach," he said. 

The U.S. company based at Roselle, Illinois, claims to be a leader in gas-fermentation technology, using proprietary microorganisms to capture waste gas streams for production of low carbon fuels and chemical intermediates.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read